+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
FEMALE
ID06824467

Evaluating Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Compared to Standard Care in Platinum-sensitive Recurrent Ovarian Cancer

Led by Merck Sharp & Dohme LLC · Updated on 2026-10-13

770

Participants Needed

198

Research Sites

184 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of sacituzumab tirumotecan combined with bevacizumab, as well as sacituzumab tirumotecan alone, compared to standard care in women with platinum-sensitive recurrent ovarian cancer. The study aims to understand if these treatments help participants live longer without their cancer worsening. This is a Phase 3, randomized, open-label trial sponsored by Merck Sharp & Dohme LLC. Participants are assigned to one of three groups. One group receives sacituzumab tirumotecan every two weeks plus bevacizumab every three weeks for six weeks. Another group receives sacituzumab tirumotecan every two weeks for up to about two years, possibly with bevacizumab at the doctors choice. The third group receives standard care, with optional bevacizumab per the physicians decision, until disease progression or discontinuation. Throughout the study, participants undergo regular intravenous infusions and are monitored for adverse events, treatment tolerance, and cancer progression. Researchers also assess quality of life using questionnaires. Safety is closely observed up to six weeks for initial side effects and for approximately four years to evaluate progression-free survival. Overall survival and long-term safety are followed for up to six years, with ongoing assessments of physical and role functioning and abdominal symptoms related to ovarian cancer.

CONDITIONS

Brief Title

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Research Team

T

Toll Free Number

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here